Hypermethylated FAM5C and MYLK in serum as diagnosis and pre-warning markers for gastric cancer

Disease Markers

Volumn 32, Issue 3, 2012, Pages 195-202

  Chen, Lu ^a,b   Su, Liping ^a,b   Li, Jianfang ^a,b   Zheng, Yanan ^a,b   Yu, Beiqin ^a,b   Yu, Yingyan ^a,b   Yan, Min ^a,b   Gu, Qinlong ^a,b   Zhu, Zhenggang ^a,b   Liu, Bingya ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

biomarker; diagnosis; FAM5C and MYLK; Gastric cancer; hypermethylated DNA; pre warning

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

ADULT; ARTICLE; BCAS4 GENE; BLOOD LEVEL; CANCER CELL CULTURE; CANCER INVASION; CANCER STAGING; CHRM2 GENE; CONTROLLED STUDY; DNA METHYLATION; FAM5C GENE; GENE; GENE IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; MYLK GENE; POLYMERASE CHAIN REACTION; PRAC GENE; PRECANCER; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; TUMOR VOLUME;

EID: 84863230241     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.3233/DMA-2011-0877     Document Type: Article

References (25)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward and D. Forman, Global cancer statistics, CA Cancer J Clin 61 (2011), 69-90.
2. S. Nomura and M. Kaminishi, Surgical treatment of early gastric cancer, Dig Surg 24 (2007), 96-100. (Pubitemid 46788274)
3. H. Tomita, A. Hirata and Y. Yamada, Suppressive effect of global DNA hypomethylation on gastric carcinogenesis, Car-cinogenesis 31 (2010), 1627-1633.
4. M. Vauhkonen, H. Vauhkonen and P. Sipponen, Pathology and molecular biology of gastric cancer, Best Pract Res Clin Gastroenterol 20 (2006), 651-674. (Pubitemid 44418021)
5. C.D. Jee, M.A. Kim, E.J. Jung, J. Kim and W.H. Kim, Identification of genes epigenetically silenced by CpG methyla-tion in human gastric carcinoma, Eur J Cancer 45 (2009), 1282-1293.
6. W. Guo, Z. Dong, Y. Guo, G. Kuang, Z. Yang and Z. Chen, Detection of promoter hypermethylation of the CpG island of E-cadherin in gastric cardiac adenocarcinoma, Eur J Med Res 14 (2009), 453-458.
7. Y.C. Wang, Z.H. Yu, C. Liu, L.Z. Xu, W. Yu and J. Lu, Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients, World J Gas-troenterol 14 (2008), 3074-3080.
8. F. Ksiaa, S. Ziadi, K. Amara, S. Korbi and M. Trimeche, Biological significance of promoter hypermethylation of tumor-related genes in patients with gastric carcinoma, Clin Chim Acta 404 (2009), 128-133.
9. J. Harder and O.G. Opitz, Gastric cancer-risk factors and medical therapy, Praxis (Bern 1994) 95 (2006), 1021-1028. (Pubitemid 44109217)
10. T. Ushijima, Detection and interpretation of altered methyla-tion patterns in cancer cells, Nat Rev Cancer 5 (2005), 223-231. (Pubitemid 40314953)
11. H. Koike, D. Ichikawa, H. Ikoma, E. Otsuji, K. Kitamura and H. Yamagishi, Comparison of methylation-specific polymerase chain reaction (MSP) with reverse transcriptase-polymerase chain reaction (RT-PCR) in peripheral blood of gastric cancer patients, J Surg Oncol 87 (2004), 182-186. (Pubitemid 39167385)
12. H. Koike, D. Ichikawa, H. Ikoma, N. Tani, D. Ikoma and E. Otsuji, Comparison of serum aberrant methylation and conventional tumor markers in gastric cancer patients, Hepato-gastroenterol 52 (2005), 1293-1296. (Pubitemid 40942233)
13. J.G. Herman, J.R. Graff, S. Myöhänen, B.D. Nelkin and S.B. Baylin, Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands, Proc Natl Acad Sci USA 93 (1996), 9821-9826. (Pubitemid 26296693)
14. H.H. Zhou, S.Y. Yan, X.Y. Zhou, X. Du, T.M. Zhang and X. Cai, MLH1 promoter germline-methylation in selected probands of Chinese hereditary non-polyposis colorectal cancer families, World J Gastroenterol 14 (2008), 7329-7334.
15. C.A. Eads, K.D. Danenberg, K. Kawakami, L.B. Saltz, C. Blake and D. Shibata, MethyLight: a high-throughput assay to measure DNA methylation, Nucleic Acids Res 28 (2000), E32.
16. Y. Hao, Y. Yu, L. Wang, M. Yan, J. Ji and Y. Qu, IPO-38 is identified as a novel serum biomarker of gastric cancer based on clinical proteomics technology, J Proteome Res 7 (2008), 3668-3677.
17. M. Carpelan-Holmström, J. Louhimo, U.H. Stenman, H. Alfthan and C. Haglund, CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers, Anticancer Res 22 (2002), 2311-2316. (Pubitemid 34857058)
18. N. Oue, Y. Mitani, J. Motoshita, S. Matsumura, K. Yoshida and H. Kuniyasu, Accumulation of DNA methylation is associated with tumor stage in gastric cancer, Cancer 106 (2006), 1250-1259. (Pubitemid 43363901)
19. M. Løvf, G.O. Thomassen and A.C. Bakken, Fusion gene mi-croarray reveals cancer type-specificity among fusion genes, Genes Chromosomes Cancer 50 (2011), 348-357.
20. S. Edwards, C. Campbell and P. Flohr, Expression analysis onto microarrays of randomly selected cDNA clones highlights HOXB13 as a marker of human prostate cancer, Br J Cancer 92 (2005), 376-381. (Pubitemid 40343155)
21. T. Kuroiwa, N. Yamamoto, T. Onda and T. Shibahara, Expression of the FAM5C in tongue squamous cell carcinoma, Oncol Rep 22 (2009), 1005-1011.
22. L.Z. Gu, W.Y. Hu, N. Antic, R. Mehta, J.R. Turner and P. de Lanerolle, Inhibiting myosin light chain kinase retards the growth of mammary and prostate cancer cells, Eur J Cancer 42, (2006), 948-957.
23. K. Kaneko, K. Satoh, A. Masamune, A. Satoh and T. Shi-mosegawa, Myosin light chain kinase inhibitors can block invasion and adhesion of human pancreatic cancer cell lines, Pancreas 24 (2002), 34-41. (Pubitemid 34019657)
24. X. Zhou, Y. Liu, J. You, H. Zhang, X. Zhang and L. Ye, Myosin light-chain kinase contributes to the proliferation and migration of breast cancer cells through cross-talk with activated ERK1/2, Cancer Lett 270 (2008), 312-327.
25. Y. Minamiya, T. Nakagawa, H. Saito, I. Matsuzaki, K. Taguchi and M. Ito, Increased expression of myosin light chain kinase mRNA is related to metastasis in non-small cell lung cancer, Tumour Biol 26 (2005), 153-157. (Pubitemid 41379755)